A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 34, Issue 5, 2004, Pages 447-453

  Grigg, Andrew P ^a   Brown, M ^a   Roberts, A W ^a   Szer, J ^a   Slavin, M A ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Allografting; Fungal prophylaxis; GVHD; Itraconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CYCLOSPORIN; ITRACONAZOLE; PREDNISOLONE;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION PREVENTION; LIVER DYSFUNCTION; MALE; MORTALITY; MOULD; MYCOSIS; NAUSEA; PILOT STUDY; PRIORITY JOURNAL; RELIABILITY; VOMITING;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; FEMALE; GASTROINTESTINAL DISEASES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS, TOXIC; HUMANS; INCIDENCE; ITRACONAZOLE; LIPOSOMES; MALE; MIDDLE AGED; PILOT PROJECTS; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 4544241909     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704614     Document Type: Article

References (44)

1. Wingard JR. Fungal infections after bone marrow transplant. Biol Blood Marrow Transplant 1999; 5: 55-68.
2. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459-1466.
3. Yuen KY, Woo PCY, Ip MSM et al. Stage-specific manifestation of mold infections in bone marrow transplant recipients: risk factors and clinical significance of positive concentrated smears. Clin Infect Dis 1997; 25: 37-42.
4. Jantunen E, Ruutu P, Niskanen L et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997; 19: 801-808.
5. Marr KA, Carter RA, Boeckh M et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-4366.
6. O'Donnell MR, Schmidt GM, Tegtmeier BR et al. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol 1994; 12: 827-834.
7. Fukuda T, Boeckh M, Carter RA et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic haematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: 827-833.
8. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet 2003; 362: 1828-1838.
9. Hovi L, Saarinen-Pihkala UM, Vettenranta K, Saxen H. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years. Bone Marrow Transplant 2000; 26: 999-1004.
10. Ribaud P, Chastang C, Latge JP et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999; 28: 322-330.
11. Grigg A. Prophylaxis and treatment of patients with aspergillosis: an overview, including the Royal Melbourne Hospital experience. J Antimicrob Chemother 2002; 49: 75-80.
12. Thursky K, Byrnes G, Grigg A et al. A predictive model for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34: 115-121.
13. Rousey SR, Russler S, Gottlieb M, Ash RC. Low-dose amphotericin B prophylaxis against invasive aspergillus infections in allogeneic marrow transplantation. Am J Med 1991; 91: 484-491.
14. Schwartz S, Behre G, Heinemann V et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999; 93: 3654-3661.
15. Tollemar J, Ringden O, Andersson S et al. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 577-582.
16. Denning DW, Hostetler JS, Kauffman CA et al. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97: 135-144.
17. Tricot G, Joosten E, Boogaerts MA et al. Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Rev Infect Dis 1987; 9: S94-S99.
18. Todeschini G, Murari C, Bonesi R et al. Oral itraconazole plus nasal amphotericin B for prophylaxis of invasive aspergillosis in patients with Hematological malignancies. Eur J Clin Microbiol Infect Dis 1993; 12: 614-618.
19. Vreugdenhil G, Van Dijke BJ, Donnelly JP et al. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymphoma 1993; 11: 353-358.
20. Morgenstern GR, Prentice AG, Prentice HG et al. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 1999; 105: 901-911.
21. Bradford CR, Prentice AG, Warnock DW, Copplestone JA. Comparison of multiple dose pharmacokinetics of two formations of itraconazole during remission induction for acute myeloblastic leukemia. J Antimicrob Chemother 1991; 28: 555-560.
22. Prentice AG, Warnock DW. Itraconazole more bioavailable in solution. Blood 1996; 88: 3662.
23. Yu VL, Muder RR, Poorsattar A. Significance of isolation of aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis. Am J Med 1986; 81: 249-254.
24. Van Cutsem J, Fan Gerven F, Janssen PAJ. Rev Infect Dis 1987; 9: 515.
25. Back DJ, Tjia JF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 1991; 32: 624-626.
26. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
27. Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomised, double-blind study. J Infect Dis 1995; 171: 1545-1552.
28. Marty FM, Lee SJ, Fahey MM et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003; 102: 2768-2776.
29. Fukuda T, Boeckh M, Carter RA et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: 827-833.
30. Glasmacher A, Prentice A, Gorschluter M et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a metaanalysis of 3,597 patients. J Clin Oncol 2003; 21: 4615-4626.
31. Winston DJ, Maziars RT, Pranatharthi H et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic haematopoietic stem-cell transplant recipients. Ann Intern Med 2003; 138: 705-713.
32. Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections in allogeneic stem cell transplant patients. Blood 2004; 103: 1527-1533.
33. Boogaerts MA, Maertens J, van Der Geest R et al. Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14 day administration of itraconazole oral solution in patients with hematologic malignancy. Antimicrobial Agents Chemother 2001; 45: 981-985.
34. Winston DJ, Emmanouilides C, Bartoni K et al. Elimination of aspergillus as a significant pathogen in an allogeneic hematopoietic stem cell transplant program after introduction of routine long-term itraconazole prophylaxis. Blood 2003; 102: 197a (Abstr. # 685).
35. Marr KA, Leisening W, Crippa F, Slattery JT et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103: 1557-1559.
36. Caillot D, Casasnovas O, Bernard A et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15: 139-147.
37. Maertens J, Verhaegen J, Lagrou K et al. Screening for circulating glactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 1604-1610.
38. Hebart H, Loffler J, Meisner C et al. Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis 2000; 181: 1713-1719.
39. Boogaerts MA, Verhoef GE, Zachee P et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989; 32: 103-108.
40. Glasmacher A, Hahn C, Molitor E et al. Definition of an itraconazole target concentration for antifungal prophylaxis. Abstracts of 40th conference on antimicrobial agents and chemotherapy, September 2000. Am Soc Microbiol 2000; 363.
41. Lamy T, Bernard M, Courtois A et al. Prophylactic use of itraconazole for the prevention of invasive pulmonary aspergillosis in high risk neutropenic patients. Leuk Lymph 1998; 30: 163-174.
42. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itracohazole. Lancet 2001; 357: 1766-1767.
43. Warris A, Weemaes CM, Veerweij PE. Multidrug resistance in aspergillus fumigatus. N Engl J Med 2002; 347: 2173-2174.
44. Westerman DA, Speed BR, Prince HM. Fatal disseminated infection by scedosporium prolificans during induction therapy for acute leukemia: a case report and literature review. Pathology 1999; 31: 393-394.